PITTSBURGH, Nov. 20, 2019 /PRNewswire/ --Highmark Health announced today that through its VITAL Innovation Platform, it is testing Moving Analytics' MOVN virtual cardiac rehabilitation solution for delivering cardiac rehab remotely to patients with heart disease. "In support of Highmark Health's mission to create a remarkable health experience, freeing people to be their best, VITAL continues to focus on major diseases and early-stage FDA-approved health innovations that show promise for improved diagnosis, treatment and return to better health," said Anil Singh, MD, Allegheny Health Network (AHN) and VITAL medical advisor. Continue reading →

PARIS--(BUSINESS WIRE)--Regulatory News: CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the worlds most advanced total artificial heart project, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announced that it has received authorization to resume the PIVOTAL study in the Czech Republic. The implants will be performed at the Institute of Clinical and Experimental Medicine (IKEM) in Prague, whose teams have benefited from a major learning curve acquired through implanting the CARMAT device during the first part of the PIVOTAL study. The screening for the second patient cohort, who will receive the new prostheses produced at the Bois-dArcy site, is already underway. Continue reading →

November 19, 2019 Since Maquet/Datascope first recalledall of itsintra-aortic balloon pumps (IABP)due to reports of the batteries failing in November 2018, a year later theU.S. Food and Drug Administration said its has received more than 60 additional medical device reports related to this issue. These included two patient deaths and one serious patient injury Continue reading →

MONMOUTH JUNCTION, N.J., Nov. 19, 2019 /PRNewswire/ --CytoSorbents Corporation(CTSO), a critical care immunotherapy leader commercializing its CytoSorbblood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that the Company will present an overview of the company at the Three Part Advisors 2019 Southwest IDEAS Investor Conference on Wednesday, November 20, 2019 in Dallas, TX, and meet with investors in 1x1 meetings throughout the day. Continue reading →

Share on PinterestA new study looks at the benefits and drawbacks of stents. Continue reading →

Cardiac Center Ethiopia (Credit: Fikir A) EteneshAbera Addis Abeba November 20/2019 Before the surgery I couldnt play with my friends, I couldnt run and I my heart would feel tired. Now I can run and play with my friends. I am very happy Afomiya, 5, says Continue reading →

While synthetic bear bile may well do little to reduce demand for the real thing in parts of Asia, it is currently being explored for some potentially phenomenal developments in western medicine For thousands of years, practitioners of traditional Chinese medicine have used bear bile as a natural treatment for a number of ailments. A digestive fluid thats produced by the liver and then stored in the gallbladder, its used principally for reducing fever and inflammation, detoxifying the liver [and] resolving gallstones, explained Dave Garshelis, a wildlife research scientist for the Minnesota Department of Natural Resources and one of the worlds leading bear experts. He also noted that the substance has anti-inflammatory properties. Continue reading →

AIMS: Deregulation of mTOR (mammalian target of rapamycin) signaling occurs in diabetes, which exacerbates injury followingmyocardial infarction. We therefore investigated the infarct-limiting effect of chronic treatment with rapamycin (RAPA, mTOR inhibitor) in diabetic mice followingmyocardialischemia/reperfusion (I/R) injury and delineated the potential protective mechanism. Adult male diabetic (db/db) or wild type (C57) mice were treated with RAPA (0.25mg/kg/day, intraperitoneal) or vehicle (5% DMSO) for 28 days. Continue reading →

Medical procedures such as inserting stents or bypass surgery aren't better (or worse) than medicines for reducing the chances of heart attack and other cardiac events in people living with stable ischemic heart disease, a landmark study, ISCHEMIA, has reported. Ischemic heart disease (IHD) occurs when cholesterol plaque builds up inside the walls of our arteries. Continue reading →